CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration
Background:
Clear, transparent, and sufficiently detailed abstracts of conferences and journal articles related to randomized controlled trials (RCTs) are important, because readers often base their assessment of a trial solely on information in the abstract. Here, we extend the CONSORT (Consolidated Standards of Reporting Trials) Statement to develop a minimum list of essential items, which authors should consider when reporting the results of a RCT in any journal or conference abstract.
Methods and Findings:
We generated a list of items from existing quality assessment tools and empirical evidence. A three-round, modified-Delphi process was used to select items. In all, 109 participants were invited to participate in an electronic survey; the response rate was 61%. Survey results were presented at a meeting of the CONSORT Group in Montebello, Canada, January 2007, involving 26 participants, including clinical trialists, statisticians, epidemiologists, and biomedical editors. Checklist items were discussed for eligibility into the final checklist. The checklist was then revised to ensure that it reflected discussions held during and subsequent to the meeting. CONSORT for Abstracts recommends that abstracts relating to RCTs have a structured format. Items should include details of trial objectives; trial design (e.g., method of allocation, blinding/masking); trial participants (i.e., description, numbers randomized, and number analyzed); interventions intended for each randomized group and their impact on primary efficacy outcomes and harms; trial conclusions; trial registration name and number; and source of funding. We recommend the checklist be used in conjunction with this explanatory document, which includes examples of good reporting, rationale, and evidence, when available, for the inclusion of each item.
Conclusions:
CONSORT for Abstracts aims to improve reporting of abstracts of RCTs published in journal articles and conference proceedings. It will help authors of abstracts of these trials provide the detail and clarity needed by readers wishing to assess a trial's validity and the applicability of its results.
Vyšlo v časopise:
CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. PLoS Med 5(1): e20. doi:10.1371/journal.pmed.0050020
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.0050020
Souhrn
Background:
Clear, transparent, and sufficiently detailed abstracts of conferences and journal articles related to randomized controlled trials (RCTs) are important, because readers often base their assessment of a trial solely on information in the abstract. Here, we extend the CONSORT (Consolidated Standards of Reporting Trials) Statement to develop a minimum list of essential items, which authors should consider when reporting the results of a RCT in any journal or conference abstract.
Methods and Findings:
We generated a list of items from existing quality assessment tools and empirical evidence. A three-round, modified-Delphi process was used to select items. In all, 109 participants were invited to participate in an electronic survey; the response rate was 61%. Survey results were presented at a meeting of the CONSORT Group in Montebello, Canada, January 2007, involving 26 participants, including clinical trialists, statisticians, epidemiologists, and biomedical editors. Checklist items were discussed for eligibility into the final checklist. The checklist was then revised to ensure that it reflected discussions held during and subsequent to the meeting. CONSORT for Abstracts recommends that abstracts relating to RCTs have a structured format. Items should include details of trial objectives; trial design (e.g., method of allocation, blinding/masking); trial participants (i.e., description, numbers randomized, and number analyzed); interventions intended for each randomized group and their impact on primary efficacy outcomes and harms; trial conclusions; trial registration name and number; and source of funding. We recommend the checklist be used in conjunction with this explanatory document, which includes examples of good reporting, rationale, and evidence, when available, for the inclusion of each item.
Conclusions:
CONSORT for Abstracts aims to improve reporting of abstracts of RCTs published in journal articles and conference proceedings. It will help authors of abstracts of these trials provide the detail and clarity needed by readers wishing to assess a trial's validity and the applicability of its results.
Zdroje
1. SchererRWLangenbergPvon ElmE
2007
Full publication of results initially presented in abstracts.
Cochrane Database of Systematic Reviews
Issue 4
Art. No.: MR000005. doi:10.1002/14651858.MR000005.pub3. Available: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/MR000005/frame.html. Accessed 1 May 2007.
2. HarbourtAMKnechtLSHumphreysBL
1995
Structured abstracts in MEDLINE, 1989–1991.
Bull Med Libr Assoc
83
190
195
3. HopewellSMcDonaldSClarkeMEggerM
2007
Grey literature in meta-analyses of randomized trials of health care interventions.
Cochrane Database of Systematic Reviews
Issue 4
Art. No.: MR000010. doi:10.1002/14651858.MR000010.pub3. Available: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/MR000010/frame.html. Accessed 1 May 2007.
4. HopewellSEisingaAClarkeM
2007
Better reporting of randomized trials in biomedical journal and conference abstracts.
J Info Sci
doi:10.1177/0165551507080415.
5. ChalmersIAdamsMDickersinKHetheringtonJTarnow-MordiW
1990
A cohort study of summary reports of controlled trials.
JAMA
263
1401
1405
6. HerbisonP
2005
The reporting quality of abstracts of randomised controlled trials submitted to the ICS meeting in Heidelberg.
Neurourol Urodyn
24
21
24
7. HopewellSClarkeM
2005
Abstracts presented at the American Society of Clinical Oncology conference: how completely are trials reported?
Clin Trials
2
265
268
8. KrzyzanowskaMKPintilieMTannockIF
2003
Factors associated with failure to publish large randomized trials presented at an oncology meeting.
JAMA
290
495
501
9. SchererR
2006
Are harms reported in abstracts of trial results from conference proceedings?
XIV Cochrane Colloquium
23–26 October,
Dublin, Ireland:
63
10. HopewellSClarkeMAskieL
2006
Reporting of trials presented in conference abstracts needs to be improved.
J Clin Epidemiol
59
681
684
11. TomaMMcAlisterFABialyLAdamsDVandermeerB
2006
Transition from meeting abstract to full-length journal article for randomized controlled trials.
JAMA
295
1281
1287
12. DundarYDoddSDicksonRWalleyTHaycoxA
2006
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
Health Technol Assess
10
1
145
13. ChokkalingamASchererRDickersinK
1998
Agreement of data abstracts compared to full publications.
Control Clin Trials
19
61S
62S
14. EstradaCABlochRMAntonacciDBasnightLLPatelSR
2000
Reporting and concordance of methodologic criteria between abstracts and articles in diagnostic test studies.
J Gen Intern Med
15
183
187
15. FroomPFroomJ
1993
Deficiencies in structured medical abstracts.
J Clin Epidemiol
46
591
594
16. HarrisAHStandardSBrunningJLCaseySLGoldergJH
2002
The accuracy of abstracts in psychology journals.
J Psychol
136
141
148
17. PitkinRMBranaganMABurmeisterLF
1999
Accuracy of data in abstracts of published research articles.
JAMA
281
1110
1111
18. WardLGKendrachMGPriceSO
2004
Accuracy of abstracts for original research articles in pharmacy journals.
Ann Pharmacother
38
1173
1177
19. IoannidisJPLauJ
2001
Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas.
JAMA
285
437
443
20. IoannidisJPEvansSJGøtzschePCO'NeillRTAltmanDG
2004
Better reporting of harms in randomized trials: an extension of the CONSORT statement.
Ann Intern Med
141
781
788
21. BeggCChoMEastwoodSHortonRMoherD
1996
Improving the quality of reporting of randomized controlled trials. The CONSORT statement.
JAMA
276
637
639
22. MoherDSchulzKFAltmanDGLepageL
2001
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.
Lancet
357
1191
1194
23. International Committee of Medical Journal Editors
2006
Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication
[Updated February 2006.] Available: http://www.icmje.org. Accessed 1 December 2006.
24. SchrigerDLAroraSAltmanDG
2006
The content of medical journal Instructions for authors.
Ann Emerg Med
48
743
749
25. Ad Hoc Working Group for Critical Appraisal of the Medical Literature
1987
A proposal for more informative abstracts of clinical articles.
Ann Intern Med
106
598
604
26. HaynesRBMulrowCDHuthEJAltmanDGGardnerMJ
1990
More informative abstracts revisited.
Ann Intern Med
113
69
76
27. HaynesRBMulrowCDHuthEJAltmanDGGardnerMJ
1996
More informative abstracts revisited.
Cleft Palate-Craniofac J
33
1
9
28. DeeksJJAltmanDG
1998
Inadequate reporting of controlled trials as short reports.
Lancet
318
193
194
29. HopewellS
2004
Impact of grey literature on systematic reviews of randomized trials
[PhD dissertation].
Oxford (UK)
Wolfson College, University of Oxford
30. HassonFKeeneySMcKennaH
2000
Research guidelines for the Delphi survey method.
J Adv Nurs
32
1008
1015
31. AltmanDGSchulzKFMoherDEggerMDavidoffF
2001
The revised CONSORT statement for reporting randomized trials: explanation and elaboration.
Ann Intern Med
134
663
694
32. BossuytPMReitsmaJBBrunsDEGatsonisCAGlasziouPP
2003
The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.
Ann Intern Med
138
W1
12
33. ThiamSLeFevreAMHaneFNdiayeABaF
2007
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial.
JAMA
297
380
386
34. DickersinKManheimerEWielandSRobinsonKALefebvreC
2002
Development of the Cochrane Collaboration's CENTRAL register of controlled clinical trials.
Eval Health Prof
25
38
64
35. CampbellMKElbourneDRAltmanDGCONSORT group
2004
CONSORT statement: extension to cluster randomised trials.
BMJ
328
702
708
36. HalonenJHalonenPJarvinenOTaskinenPAuvinenT
2007
Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.
JAMA
297
1562
1567
37. OosterheertJJBontenMJSchneiderMMBuskensELammersJW
2006
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
BMJ
33
1193
38. MebazaaANieminenMSPackerMCohen-SolalAKleberFX
2007
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial.
JAMA
297
1883
1891
39. ChanAWHrobjartssonAHaahrMTGøtzschePCAltmanDG
2004A
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.
JAMA
291
2457
2465
40. ChanAWAltmanDG
2004B
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors.
BMJ
330
753
41. WilliamsonPRGambleC
2005
Identification and impact of outcome selection bias in meta-analysis.
Stat Med
24
1547
1561
42. JohnsonNPFarquharCMHaddenWESucklingJYuY
2004
The FLUSH trial: flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial.
Hum Reprod
19
2043
2051
43. GluudLL
2006
Bias in clinical intervention research.
Am J Epidemiol
163
493
501
44. PildalJHrobjartssonAJorgensenKHildenJAltmanD
2007
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials.
Int J Epidemiol
36
847
857
45. JuniPAltmanDGEggerM
2001
Systematic reviews in health care: assessing the quality of controlled clinical trials.
BMJ
323
42
46
46. SchulzKFGrimesDA
2002
Allocation concealment in randomised trials: defending against deciphering.
Lancet
359
614
618
47. SchererRWCrawleyB
1998
Reporting of randomized clinical trial descriptors and use of structured abstracts.
JAMA
280
269
272
48. BurnsKEAAdhikariNKJKhoMMeadeMOPatelRV
2005
Abstract reporting in randomized clinical trials of acute lung injury: an audit and assessment of a quality of reporting score.
Crit Care Med
33
1937
1945
49. TaddioAPainTFassosFFBoonHIlersichAL
1994
Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association.
CMAJ
150
1611
1618
50. ClarkEPlintACCorrellRGabouryIPassiB
2007
A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma.
Pediatrics
119
460
467
51. SchulzKFGrimesDA
2006
The Lancet handbook of essential concepts in clinical research
London
Elsevier
52. SchulzKFAltmanDGMoherD
2007
Blinding is better than masking.
BMJ
334
918
53. DevereauxPJMannsBJGhaliWAQuanHLacchettiC
2001
Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials.
JAMA
285
2000
2003
54. PoolmanRWStruijsPAKripsRSiereveltINMartiRK
2007
Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter?
J Bone Joint Surg
89-A
550
558
55. SazawalSDhingraUDhingraPHiremathGKumarJ
2007
Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial.
BMJ
334
140
56. KimKBLeghaSSGonzalezRAndersonCPapadopoulosNE
2006
A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
J Clin Oncol
ASCO Annual Meeting Proceedings Part I. Vol
24
8003
57. PocockSJHughesMDLeeRJ
1987
Statistical problems in the reporting of clinical trials.
N Engl J Med
317
426
432
58. MontoriVMDevereauxPJAdhikariNKBurnsKEEggertCH
2005
Randomized trials stopped early for benefit: a systematic review.
JAMA
294
2203
2209
59. BhandariMDevereauxPJGuyattGHCookDJSwiontkowskiMF
2002
An observational study of orthopaedic abstracts and subsequent full-text publications.
J Bone Joint Surg
84-A
615
621
60. DryverEHuxJE
2002
Reporting of numerical and statistical differences in abstracts: improving but not optimal.
J Gen Intern Med
17
203
206
61. GøtzschePC
2006
Believability of relative risks and odds ratios in abstracts: cross sectional study.
BMJ
333
231
234
62. SchwartzLMWoloshinSDvorinELWelchHG
2006
Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks.
BMJ
333
1248
1250
63. JohnsonBARosenthalNCapeceJAWiegandFMaoL
2007
Topiramate for treating alcohol dependence: a randomized controlled trial.
JAMA
298
1641
1651
64. DerrySKong LokeYAronsonJK
2001
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials.
BMC Med Res Methodol
1
7
65. FawziWWMsamangaGIUrassaWHertzmarkEPetraroP
2007
Vitamins and perinatal outcomes among HIV-negative women in Tanzania.
N Engl J Med
356
1423
1431
66. DickersinK
1997
How important is publication bias? A synthesis of available data.
AIDS Educ Prev
9
Supplement A
15
21
67. TramerMRReynoldsDJMooreRAMcQuayHJ
1997
Impact of covert duplicate publication on meta-analysis: a case study.
BMJ
315
635
640
68. SimesRJ
1986
Publication bias: the case for an international registry of clinical trials.
J Clin Oncol
4
1529
1541
69. WhittingtonCJKendallTFonagyPCottrellDCotgroveA
2004
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
Lancet
363
1341
1345
70. De AngelisCDDrazenJMFrizelleFAHaugCHoeyJ
2005
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors.
Lancet
365
1827
1829
71. ZarinDAIdeNCTseTHarlanWRWestJC
2007
Issues in the registration of clinical trials.
JAMA
297
2112
2120
72. ZellarsRCFrassicaDStearnsVFettingJHArmstrongDK
2006
Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial.
J Clin Oncol
ASCO Annual Meeting Proceedings Part I.
Vol 24
No. 18S (June 20 Supplement), 2006
10675
73. LexchinJBeroLADjulbegovicBClarkO
2003
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ
326
1167
1170
74. BeroLOostvogelFBacchettiPLeeK
2007
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
PLoS Med
4
e184
doi: 10.1371/journal.pmed.0040184
75. HartleyJ
2004
Current findings from research on structured abstracts.
J Med Libr Assoc
92
368
371
76. GuimaraesCA
2006
Structured abstracts: narrative review.
Acta Cir Bras
21
263
268
77. SollaciLBPereiraMG
2004
The introduction, methods, results, and discussion (IMRAD) structure: a fifty-year survey.
J Med Libr Assoc
92
364
367
78. GulmezogluAMPangTHortonRDickersinK
2005
WHO facilitates international collaboration in setting standards for clinical trial registration.
Lancet
365
1829
1831
79. World Health Organisation
2007
International Clinical Trials Registry Platform
http://www.who.int/ictrp/en/. Accessed 12 June 2007.
80. LaineCHortonRDeangelisCDDrazenJMFrizelleFA
2007
Clinical trial registration: looking back and moving ahead.
BMJ
334
1177
1178
81. PiaggioGElbourneDRAltmanDGPocockSJEvansSJW
2006
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
JAMA
295
1152
1160
82. National Library of Medicine
2007
MEDLINE / PubMed data element (field) descriptions
Available: http://www.nlm.nih.gov/bsd/mms/medlineelements.html. Accessed 16 April 2007.
83. HillCLBuchbinderROsborneR
2007
Quality of reporting of randomized clinical trials in abstracts of the 2005 Annual Meeting of the American College of Rheumatology.
J Rheumatol
34
2476
2480
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2008 Číslo 1
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Model-Based Insights into Multi-Host Transmission and Control of Schistosomiasis
- New Insights into Impaired Muscle Glycogen Synthesis
- Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model
- The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States